Drugs / 177Lu-EB-PSMA-617
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04801264 | Sep 2020 → Sep 2022 | adenoid cystic carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03780075 | Apr 2018 → Sep 2020 | prostate carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03403595 | Dec 2017 → Dec 2018 | prostate carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05170555 | Dec 2021 → Oct 2022 | renal cell carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-EB-PSMA-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03780075 ↗ |
| Modality | Other / unclassified | “who will undergo radioliagnd therapy using 177Lu-EB-PSMA-617.” NCT03403595 ↗ |
| Route | Intravenous | “accepted intravenous injection of 177Lu-EB-PSMA-617” NCT03403595 ↗ |